Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial introductions

Editorial introductions Downloaded from https://pdfs.journals.lww.com/co-hivandaids by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qj/1S0ZObgiiKJ9vD64yNdY1wI1G/v4gN3ti1fujtTJsg5898WZFuC on 02/20/2019 URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS describing the reconstitution of antigen specific CD4þ T cell responses in patients receiving Mathias Lichterfeld potent anti-retroviral therapy in the context of an early phase trial of the HIV protease inhibitor, Ritonavir. Mathias Lichterfeld is an Infec- He completed a post doc in Oxford, United tious Disease Physician at the Kingdom, at the Weatherall Institute of Molecular Brigham and Women’s Hospital Medicine and Nuffield Department of Medicine in Boston, USA, and an Associate where he studied the coevolution of HIV and the Professor of Medicine at Harvard viral immune response. He was the first to describe Medical School, USA. He received the requirement of compensatory mutations in the his MD/PhD degree from the process of delayed immune escape from CD8þ Tcell Ruprecht-Karls University in Hei- responses. He also developed a methodology for the delberg, Germany and completed production of Class II MHC tetramers. residency and infectious disease subspecialty train- He returned to Sydney in 2001 to join an Aus- ing at Massachusetts General Hospital and the Brig- tralian consortium developing a prophylactic HIV ham and Women’s Hospital in Boston, vaccine based on a prime boost strategy which Massachusetts. His scientific interests focus on the successfully completed clinical trials in Australia analysis of HIV-1 reservoir cells and on the develop- and Thailand. ment of clinical strategies for HIV-1 cure He has played a role in multiple phase 1 to phase and eradication. IV clinical trials and cohort studies exploring the treatment and prevention of HIV infection, espe- cially in the conduct of correlative laboratory based Tony Kelleher studies. More recently he has established novel assays for the measurement of CD4þ Tcell responses and the use of fine needle biopsies of Tony Kelleher is a clinician scien- tist. He graduated from Medicine lymph nodes to study both immune responses at University of New South Wales and the HIV reservoir. He is also exploring an siRNA (UNSW), Australia, in 1986. He based block and lock strategy for the control of the trained in internal medicine and viral reservoir. pathology at St Vincent’s Hospi- He is currently head of the Immunovirology and tal, Sydney, Australia, at the Pathogenesis program at the Kirby Institute, height of the HIV epidemic qual- Australia, Principal of the Infection Immunology ifying as a Clinical Immunologist and Inflammation Theme and Senior Vice Dean and Immunopathologist in 1995. Research of UNSW Medicine. He is a clinical aca- He completed his PhD in 1997, describing the demic at St Vincent’s Hospital Sydney responsible modulation of the HIV infected immune system by a for clinical care of patients with HIV infection and range of interventions including therapeutic vac- autoimmune diseases as well as oversight of the cines and IL-2. He made the first observations NSW State HIV Reference laboratory. 1746-630X Copyright  2019 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. Downloaded from https://pdfs.journals.lww.com/co-hivandaids by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qj/1S0ZObgiiKJ9vD64yNdY1wI1G/v4gN3ti1fujtTJsg5898WZFuC on 02/20/2019 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

Editorial introductions

Current Opinion in HIV and AIDS , Volume 14 (2) – Mar 1, 2019
Download PDF
1 page

Loading next page...
 
/lp/wolters-kluwer-health/editorial-introductions-0gxFjAevCN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000533
Publisher site
See Article on Publisher Site

Abstract

Downloaded from https://pdfs.journals.lww.com/co-hivandaids by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qj/1S0ZObgiiKJ9vD64yNdY1wI1G/v4gN3ti1fujtTJsg5898WZFuC on 02/20/2019 URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue. SECTION EDITORS describing the reconstitution of antigen specific CD4þ T cell responses in patients receiving Mathias Lichterfeld potent anti-retroviral therapy in the context of an early phase trial of the HIV protease inhibitor, Ritonavir. Mathias Lichterfeld is an Infec- He completed a post doc in Oxford, United tious Disease Physician at the Kingdom, at the Weatherall Institute of Molecular Brigham and Women’s Hospital Medicine and Nuffield Department of Medicine in Boston, USA, and an Associate where he studied the coevolution of HIV and the Professor of Medicine at Harvard viral immune response. He was the first to describe Medical School, USA. He received the requirement of compensatory mutations in the his MD/PhD degree from the process of delayed immune escape from CD8þ Tcell Ruprecht-Karls University in Hei- responses. He also developed a methodology for the delberg, Germany and completed production of Class II MHC tetramers. residency and infectious disease subspecialty train- He returned to Sydney in 2001 to join an Aus- ing at Massachusetts General Hospital and the Brig- tralian consortium developing a prophylactic HIV ham and Women’s Hospital in Boston, vaccine based on a prime boost strategy which Massachusetts. His scientific interests focus on the successfully completed clinical trials in Australia analysis of HIV-1 reservoir cells and on the develop- and Thailand. ment of clinical strategies for HIV-1 cure He has played a role in multiple phase 1 to phase and eradication. IV clinical trials and cohort studies exploring the treatment and prevention of HIV infection, espe- cially in the conduct of correlative laboratory based Tony Kelleher studies. More recently he has established novel assays for the measurement of CD4þ Tcell responses and the use of fine needle biopsies of Tony Kelleher is a clinician scien- tist. He graduated from Medicine lymph nodes to study both immune responses at University of New South Wales and the HIV reservoir. He is also exploring an siRNA (UNSW), Australia, in 1986. He based block and lock strategy for the control of the trained in internal medicine and viral reservoir. pathology at St Vincent’s Hospi- He is currently head of the Immunovirology and tal, Sydney, Australia, at the Pathogenesis program at the Kirby Institute, height of the HIV epidemic qual- Australia, Principal of the Infection Immunology ifying as a Clinical Immunologist and Inflammation Theme and Senior Vice Dean and Immunopathologist in 1995. Research of UNSW Medicine. He is a clinical aca- He completed his PhD in 1997, describing the demic at St Vincent’s Hospital Sydney responsible modulation of the HIV infected immune system by a for clinical care of patients with HIV infection and range of interventions including therapeutic vac- autoimmune diseases as well as oversight of the cines and IL-2. He made the first observations NSW State HIV Reference laboratory. 1746-630X Copyright  2019 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. Downloaded from https://pdfs.journals.lww.com/co-hivandaids by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qj/1S0ZObgiiKJ9vD64yNdY1wI1G/v4gN3ti1fujtTJsg5898WZFuC on 02/20/2019

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Mar 1, 2019

There are no references for this article.